List of Excipients in Branded Drug MINASTRIN 24 FE

« Back to Dashboard

Minastrin 24 Fe uses an excipient architecture designed around four commercial requirements: chewability, low-dose hormone uniformity, masking of hormonal and iron-related taste, and clear separation between 24 active tablets and four ferrous fumarate tablets. The strongest opportunities are generic or authorized-generic reformulation, lactose-free and improved taste profiles, direct-to-consumer contraceptive differentiation, and excipient supply agreements.

Last updated: August 26, 2026

Minastrin 24 Fe Excipient Strategy and Commercial Opportunities

What is Minastrin 24 Fe and how is it formulated?

Minastrin 24 Fe is an oral contraceptive containing norethindrone acetate and ethinyl estradiol in 24 chewable active tablets, followed by four tablets containing ferrous fumarate. Warner Chilcott developed the product; the U.S. product was later associated with Allergan and AbbVie portfolios. The FDA approved Minastrin 24 Fe under NDA 022684 in 2013.[1]

The product combines:

Product component	Function	Commercial relevance
Norethindrone acetate	Progestin	Requires dose uniformity and chemical stability
Ethinyl estradiol	Estrogen	Present at a very low dose, increasing content-uniformity risk
Ferrous fumarate	Iron-containing tablets	Provides the four non-hormonal tablets in the 28-day regimen
Chewable tablet platform	Delivery system	Creates taste, mouthfeel, hardness and disintegration requirements
24/4 regimen	Dosing architecture	Supports adherence and differentiation from standard 21/7 oral contraceptives

The FDA labeling identifies conventional tablet excipient classes, including lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, hypromellose, talc and colorants. The active and ferrous fumarate tablets are formulated as separate dosage units rather than as a single combined tablet.[1]

Why the 24/4 architecture matters

The four ferrous fumarate tablets are not hormone-containing tablets. They maintain the tablet-taking routine during the menstrual interval and reduce the need for a separate placebo tablet. This arrangement also gives the sponsor greater formulation flexibility because the hormonal and iron-containing units can be optimized independently.

The active tablets require:

• Uniform distribution of 1 mg norethindrone acetate and 20 mcg ethinyl estradiol.
• Acceptable taste after chewing.
• Rapid disintegration without excessive friability.
• Stable performance under moisture and temperature stress.
• Consistent tablet weight and mechanical strength.

The ferrous fumarate tablets require a different design target. Iron compounds can create metallic taste, discoloration, odor, and gastrointestinal tolerability concerns. The inactive tablets therefore offer a separate opportunity for coating, flavor control and mineral taste masking.

Which excipients are commercially important in Minastrin 24 Fe?

Fillers and compression aids

Lactose monohydrate and microcrystalline cellulose provide bulk and support tablet formation. Microcrystalline cellulose is particularly relevant because a low-dose hormonal tablet needs sufficient excipient mass to achieve reliable content uniformity.

A generic manufacturer could replace lactose with mannitol, spray-dried lactose, dibasic calcium phosphate or a co-processed excipient. Each substitution changes powder flow, compactibility, disintegration and sensory performance.

The commercial opportunity is strongest for:

• Lactose-free formulations.
• Lower-moisture formulations.
• Direct-compression systems.
• Excipient blends optimized for low-dose drug distribution.
• Reduced friability during packaging and shipping.

A lactose-free version could appeal to patients with lactose intolerance and to manufacturers seeking a cleaner label. The change would require comparative dissolution, stability and bioequivalence work because a filler change can affect the release of a low-dose hormone.

Superdisintegrants

Croscarmellose sodium supports rapid tablet breakup after chewing and swallowing. Generic developers can evaluate crospovidone, sodium starch glycolate or combinations of superdisintegrants.

The most valuable formulation target is not simply faster disintegration. It is a balance between:

• Rapid breakup.
• Adequate tablet strength.
• Low friability.
• Acceptable mouthfeel.
• Consistent dissolution after partial chewing.

Excessive superdisintegrant levels can create a rough or chalky mouthfeel. Insufficient levels can produce a dense tablet that is difficult to chew and may show slower drug release.

Lubricants and processing excipients

Magnesium stearate supports tablet ejection but can reduce wettability or slow dissolution when over-lubrication occurs. This is material for both formulation optimization and excipient-supplier differentiation.

Potential alternatives include sodium stearyl fumarate and lower-level magnesium stearate systems. The commercial case is strongest where a manufacturer can demonstrate improved dissolution robustness without increasing manufacturing complexity.

Film-forming and protective excipients

Hypromellose and talc can support coating, appearance and handling. Coating is commercially important because it can reduce direct contact between the patient’s tongue and the active tablet, although excessive coating may undermine the chewable profile.

An optimized coating system may offer:

• Better taste masking.
• Lower dusting.
• Improved color stability.
• Reduced moisture uptake.
• More consistent tablet identity during the 28-day regimen.

What excipient strategy best addresses taste and mouthfeel?

Taste is the main technical barrier to a differentiated Minastrin 24 Fe formulation. Both hormonal actives and iron compounds can create an unpleasant sensory profile. A chewable contraceptive exposes the formulation to the mouth, unlike a conventional swallowable tablet.

Taste-masking options

Potential strategies include:

1. Polymer coating of drug particles. Ethylcellulose, hypromellose or methacrylate-based polymers can reduce immediate exposure of the drug to taste receptors.
2. Ion-exchange or adsorbent systems. These can reduce the free concentration of bitter drug at the tongue.
3. Sweetener and flavor systems. Sucralose, acesulfame potassium, saccharin, mannitol and selected fruit or mint flavors are possible tools.
4. Multiparticulate or granulated systems. Drug-loaded particles can improve distribution and reduce concentrated bitter spots.
5. Iron-specific masking. Coating or complexation can reduce metallic taste and discoloration from ferrous fumarate.

A commercially attractive formulation would preserve the small, convenient chewable tablet while reducing bitterness without relying on high levels of sugar or polyols.

Mouthfeel constraints

A formulation can pass dissolution and still fail commercially if it feels gritty, sticks to the teeth or leaves a metallic aftertaste. The relevant performance tests should include:

• Texture profile analysis.
• Breaking force and friability.
• Particle-size distribution.
• Sensory evaluation.
• Residual taste after 5 to 15 minutes.
• Dissolution following simulated chewing or mechanical agitation.

Excipients that improve taste but create a waxy or gritty texture are unlikely to support a premium product.

What formulation patents may protect Minastrin 24 Fe?

Minastrin 24 Fe’s commercial protection has historically depended more on formulation and dosage-regimen claims than on broad composition-of-matter protection. The active ingredients, norethindrone acetate and ethinyl estradiol, are long-established molecules.

Potential claim categories include:

• Chewable oral contraceptive compositions.
• Specific ratios or concentrations of norethindrone acetate and ethinyl estradiol.
• Tablet hardness, disintegration or dissolution parameters.
• Use of ferrous fumarate in a 24/4 regimen.
• Taste-masked hormone particles.
• Specific excipient combinations.
• Manufacturing processes for low-dose uniformity.
• Packaging systems that control moisture or oxygen.

A generic developer must distinguish between formulation similarity required for FDA approval and patent infringement risk. FDA approval does not eliminate exposure to formulation, method-of-use or manufacturing patents.

Historically, patents associated with Minastrin 24 Fe were subject to Hatch-Waxman litigation and Paragraph IV activity. Current patent status, Orange Book listings and enforceability must be checked against the latest FDA Orange Book, USPTO records and litigation docket because patent expiration, terminal disclaimers, pediatric extensions and delisting can change the entry analysis.[2][3]

What is the Orange Book and FDA regulatory status of Minastrin 24 Fe?

Minastrin 24 Fe was approved through the 505(b)(1) NDA pathway. A generic competitor would generally pursue an ANDA demonstrating pharmaceutical equivalence and bioequivalence to the reference-listed drug, subject to FDA requirements for chewable tablets and the specific drug product.[1][4]

Key regulatory issues include:

Regulatory issue	Relevance to a generic or reformulated product
Dosage form	Chewable tablets must perform as chewable tablets, not merely as conventional tablets
Strength	The hormonal strengths must match the reference product
Regimen	The 24 active/4 ferrous fumarate configuration is commercially central
Inactive ingredients	Differences may be permitted but must not create safety or performance problems
Bioequivalence	Requires appropriate comparative evidence under the FDA product-specific framework
Labeling	The product must conform to the approved contraceptive labeling
Patent certification	Paragraph III, Paragraph IV or other certifications may affect launch timing

An authorized generic or licensed product can reduce development risk where the sponsor has access to the reference formulation, manufacturing data or brand supply chain. A fully independent ANDA sponsor has more room to redesign excipients but assumes greater bioequivalence and CMC risk.

When does Minastrin 24 Fe lose exclusivity?

Regulatory exclusivity and patent exclusivity are separate.

The FDA’s 2013 approval created a period of new-drug exclusivity, but that period is distinct from any later-expiring formulation patents. The commercial entry date depends on the surviving Orange Book patents, litigation outcomes, settlement terms and any applicable pediatric extension.[2]

For a launch assessment, companies should model at least four scenarios:

Launch scenario	Main condition
Earliest approved entry	No blocking patent or successful Paragraph IV outcome
At-risk launch	ANDA approval occurs before final patent resolution
Settlement-based launch	Entry occurs on a negotiated date
Post-expiration launch	Entry follows the last enforceable patent or exclusivity period

Because Minastrin 24 Fe is an older branded product and because generic norethindrone acetate/ethinyl estradiol products already occupy the broader contraceptive market, the central question is likely product-specific chewable and regimen protection rather than basic hormone protection.

Which companies are likely to challenge or compete with Minastrin 24 Fe?

Competition can come from three groups:

Generic manufacturers

Companies with oral-solid-dose and hormonal-product capabilities can target the product through an ANDA. Their main technical barriers are low-dose content uniformity, taste masking, chewable performance and the four-tablet ferrous fumarate component.

Branded contraceptive companies

Branded competitors can differentiate through:

• Lower monthly cost.
• Better taste.
• Lactose-free labeling.
• Alternative packaging.
• Telehealth distribution.
• Extended-cycle dosing.
• Patient support and adherence programs.

Excipient and contract-development suppliers

Suppliers of co-processed fillers, taste-masking polymers, direct-compression systems and iron-masking technologies can pursue licensing or development agreements with generic manufacturers.

The most defensible commercial position may be a platform technology that can be used across multiple chewable hormonal products rather than a single-product excipient formulation.

What licensing and partnership opportunities exist?

Potential transaction structures include:

1. Excipient technology license. A polymer-coated hormone or iron-masking system is licensed to an ANDA sponsor.
2. Co-development agreement. An excipient supplier funds formulation development in exchange for volume commitments or royalties.
3. Authorized-generic arrangement. The brand owner supplies the reference product or grants rights to a generic partner.
4. Private-label supply agreement. A contract manufacturer supplies a chewable contraceptive to telehealth or pharmacy brands.
5. Geographic license. Rights are granted outside the United States where patent and regulatory positions differ.
6. Technology transfer. A sponsor transfers a taste-masking or low-dose uniformity process to a regional manufacturer.

The commercial value of a license will depend on whether the excipient system creates a measurable regulatory advantage, a patent position, lower manufacturing cost or a product characteristic that patients can perceive.

What geographic opportunities exist?

The United States offers the clearest ANDA pathway but also the most developed patent and litigation framework. Europe, Canada, Latin America and selected Asian markets may offer opportunities for chewable combined oral contraceptives, but approval requirements and contraceptive labeling differ by jurisdiction.

Geographic strategy should evaluate:

• Local availability of norethindrone acetate and ethinyl estradiol.
• Whether ferrous fumarate is treated as an active ingredient or supplement component.
• Local requirements for chewable dosage forms.
• Excipients permitted in pediatric or reproductive-health products.
• Patent term and data-exclusivity status.
• Local tender and reimbursement pricing.
• Stability requirements in hot and humid climates.

Moisture protection is especially important for markets with high humidity. Blister packaging with appropriate barrier properties may be as commercially important as the tablet formulation.

How strong is the commercial patent estate for Minastrin 24 Fe?

The estate is stronger where claims cover the specific chewable platform, 24/4 regimen, excipient combination or manufacturing process. It is weaker against a competitor that uses:

• Different fillers and binders.
• A distinct taste-masking mechanism.
• An independently optimized coating.
• A different manufacturing sequence.
• A non-infringing packaging configuration.

The principal generic-entry risks are not limited to active-ingredient patents. They include formulation patents, process patents, method-of-use patents and litigation-driven launch delays.

A practical freedom-to-operate review should map each proposed formulation against:

• Orange Book-listed patents.
• Unlisted formulation and process patents.
• Continuations and divisionals.
• Patent-term adjustments.
• Terminal disclaimers.
• Prior litigation and claim construction.
• Settlement restrictions.
• Foreign counterparts.

Key Takeaways

• Minastrin 24 Fe is a 24/4 chewable contraceptive containing norethindrone acetate, ethinyl estradiol and four ferrous fumarate tablets.
• The key excipient challenges are taste masking, low-dose content uniformity, chewability, tablet strength and iron-related metallic taste.
• Lactose-free, low-moisture and improved-sensory formulations are the clearest product opportunities.
• A generic developer must treat the hormonal tablets and ferrous fumarate tablets as separate formulation problems.
• The most valuable IP is likely to reside in chewable composition, excipient combinations, taste masking, manufacturing and regimen claims rather than in the old active ingredients.
• Licensing opportunities exist for excipient platforms, authorized generics, private-label products and regional commercialization.
• Current launch timing requires a live Orange Book, USPTO and litigation review.

FAQs

Can Minastrin 24 Fe be reformulated without lactose?

Yes. A generic or follow-on product may use alternative fillers if the formulation meets FDA requirements for safety, pharmaceutical equivalence and bioequivalence. Mannitol and co-processed direct-compression excipients are potential substitutes, but taste, dissolution and stability must be reassessed.

Why does Minastrin 24 Fe use ferrous fumarate instead of a conventional placebo?

Ferrous fumarate provides the non-hormonal tablets used during the final four days of the 28-day regimen. The tablets preserve daily dosing behavior while supplying iron-containing tablets rather than inert placebos.

Is a chewable contraceptive harder to develop than a swallowable tablet?

Usually. Chewable products require acceptable taste, texture and residual mouthfeel in addition to conventional tablet performance. Low-dose hormonal content uniformity further increases development complexity.

Can an excipient supplier obtain patent protection for a Minastrin 24 Fe substitute?

Potentially. Protection may be available for a novel taste-masking system, excipient combination, coated-particle architecture, manufacturing process or stability-enhancing package. Patentability depends on novelty, non-obviousness and claim scope.

What is the most attractive commercial niche for a Minastrin 24 Fe competitor?

A lactose-free, low-cost chewable oral contraceptive with improved taste, reliable 24/4 packaging and broad pharmacy or telehealth distribution is the strongest differentiated concept. Its commercial value would depend on regulatory approval, patent freedom to operate and reimbursement economics.

References

1. U.S. Food and Drug Administration. (2013). Minastrin 24 Fe prescribing information, NDA 022684. FDA Drugs@FDA.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
3. United States Patent and Trademark Office. (2024). Patent Center and Patent Examination Data System. USPTO.
4. U.S. Food and Drug Administration. (2021). Draft guidance for industry: Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA. FDA.